We wonÂ’t improve cancer care until we know more about how well we are doing and how alternative approaches compare. It sounds obvious, but itÂ’s not happening, says Â“the realÂ” David Cameron
EORTC boosts efforts to address the long-term problems faced by people who have been treated for cancer.
Joining a clinical trial can be a lifeline for patients with few options open to them. But are outdated attitudes and practices preventing them from benefiting as much as they could?
Could the new generation of antibodyÂ–drug conjugates herald a move away from conventional untargeted chemotherapy? Much will depend on how far Â– and in whom Â– their added benefit can justify the high cost of these technologically sophisticated drugs.
Understanding the impact of treating the mother on the long-term health of her unborn child has long been held back by logistical and ethical obstacles to
researching this rare patient population. FrĂ©dĂ©ric Amant took up the challenge.
Exercise reduces the risks of getting some cancers Â– but what about after diagnosis? What should we be advising our patients?